Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ramipril · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Ramipril | EXPERIMENTAL | Ramipril 10 mg capsules of Dr. Reddy's Laboratories Limited |
| Altace | ACTIVE_COMPARATOR | Altace@ 10 mg capsules of Kings Pharmaceuticals, USA |
| Name | Type | Description |
|---|---|---|
| Ramipril | DRUG | Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited |
| Altace | DRUG | Altace@ 10 mg capsules of Kings Pharmaceuticals, USA |
Inclusion Criteria: 1. Healthy males between 18 and 45 years of age (both inclusive) living in and around Ahmedabad city of western part of India. 2. Having a Body Mass Index (BMI) between 18.5 and 24.9 (both inclusive), calculated as weight in kg/height in m2 3. Not having any significant diseases...
Ramipril is a small molecule drug developed by Dr. Reddy's Laboratories Ltd. It is an ACE inhibitor, and the company has studied it in Phase 1 clinical trials. The specific therapeutic indication for this program is undisclosed.
Ramipril targets ACE, or angiotensin-converting enzyme. It acts as an inhibitor of this enzyme. By inhibiting ACE, the drug affects the renin-angiotensin system, which is involved in blood pressure regulation.
Ramipril is being developed by Dr. Reddy's Laboratories Ltd, which trades under the ticker RDY. The company sponsored the clinical trials evaluating this drug candidate.
Ramipril is in Phase 1 clinical development. Dr. Reddy's Laboratories Ltd has completed two Phase 1 trials of the drug. It is an investigational product and has not been approved by the FDA for any indication.
Ramipril has been studied in two completed Phase 1 trials: NCT01164774, a bioavailability study under non-fasting conditions, and NCT01164761, a bioavailability study under fasting conditions. Both enrolled 54 healthy male volunteers in India.